Background: Thyroid cancer: The incidence of thyroid cancer has doubled over the last two decades. Although most patients with thyroid cancer of follicular cell origin have an excellent prognosis, 10% - 15% will have refractory disease to conventional therapy (resection combined with radioiodine ablation and thyroid hormone for TSH suppression). Chemotherapy and external beam radiation are ineffective in patients with metastatic disease. The overall 10 year survival of patients with metastatic thyroid cancer of follicular cell origin is approximately 40-50%. Adrenocortical carcinoma: Approximately two-thirds of patients who present with adrenocortical carcinoma have locoregional disease and metastasis. Unfortunately, despite combined multimodality therapy, the overall prognosis of patients with adrenocortical carcinoma remains dismal, with a 5-year survival of less than 35%. Summary: We have made progress towards identifying molecular targets and novel agents for endocrine cancer therapy. From our pangenomic studies of endocrine cancers (thyroid and adrenal), we have identified altered genes/pathways which are druggable targets. By integrating this data with quantitative high throughput screening of over 3,000 compounds, which showed anticancer activity in thyroid and adrenal cell lines, we have identified compounds uniformly effective across all cancer cell lines studied and with different driver mutations. We are currently validating the activities of these compounds in vivo as well as performing matrix drug screening of compounds with established standard of care drugs for combination therapy evaluation. Based on this work we are also currently developing two clinical protocols for anaplastic thyroid cancer and adrenal cancer.
|Peng, Hongzhuang; Talebzadeh-Farrooji, Mehdi; Osborne, Michael J et al. (2014) LIMD2 is a small LIM-only protein overexpressed in metastatic lesions that regulates cell motility and tumor progression by directly binding to and activating the integrin-linked kinase. Cancer Res 74:1390-403|
|Ellis, Ryan J; Wang, Yonghong; Stevenson, Holly S et al. (2014) Genome-wide methylation patterns in papillary thyroid cancer are distinct based on histological subtype and tumor genotype. J Clin Endocrinol Metab 99:E329-37|
|Desai, Shruti S; Modali, Sita D; Parekh, Vaishali I et al. (2014) GSK-3? protein phosphorylates and stabilizes HLXB9 protein in insulinoma cells to form a targetable mechanism of controlling insulinoma cell proliferation. J Biol Chem 289:5386-98|
|Nilubol, Naris; Boufraqech, Myriem; Zhang, Lisa et al. (2014) Loss of CPSF2 expression is associated with increased thyroid cancer cellular invasion and cancer stem cell population, and more aggressive disease. J Clin Endocrinol Metab 99:E1173-82|
|Boufraqech, Myriem; Zhang, Lisa; Jain, Meenu et al. (2014) miR-145 suppresses thyroid cancer growth and metastasis and targets AKT3. Endocr Relat Cancer 21:517-31|
|Zhang, Lisa; Gaskins, Kelli; Yu, Zhiya et al. (2014) An in vivo mouse model of metastatic human thyroid cancer. Thyroid 24:695-704|
|Howard, Brandi; Wang, Yonghong; Xekouki, Paraskevi et al. (2014) Integrated analysis of genome-wide methylation and gene expression shows epigenetic regulation of CYP11B2 in aldosteronomas. J Clin Endocrinol Metab 99:E536-43|